key: cord-0812721-3ugbuavv
authors: Banerji, Aleena; Phillips, Elizabeth; Saff, Rebecca; Wickner, Paige G.; Robinson, Lacey B.; Wolfson, Anna R.; Williams, Paul; Khan, David A.; Blumenthal, Kimberly G.
title: Reply to “PEG skin testing for COVID-19 allergy”
date: 2021-04-07
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.02.015
sha: 0f7f1119dd86cb128e0c46d938aecd190df6b283
doc_id: 812721
cord_uid: 3ugbuavv

nan

To the Editor:

I read with great interest the special article entitled ''mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach'' by Banerji et al in the Journal of Allergy and Clinical Immunology: In Practice. 1 I would like to ask the authors to justify their recommendation for polyethylene glycol (PEG) skin testing for those patients in the ''higher risk'' for reaction to vaccine category.

The authors state that they do not recommend skin testing with the vaccine because of ''lack of information about sensitivity or specificity (and) unclear safety of skin testing.''

The authors also state that PEG skin testing ''could be considered'' and ''may be of value in shared decision making'' in spite of also stating that ''there is no confirmation IgE mediated reactions to PEG are responsible for reported reactions to the....COVID-19 vaccines.'' Therefore, a skin test could be helpful when positive but does not rule out allergy when negative.

Allergists performing PEG skin testing can therefore be deluding themselves until they stumble across a false negative. If lack of information about sensitivity is a reason not to skin test with the vaccine, why isn't it a reason not to skin test with PEG? Reply to ''PEG skin testing for COVID-19 allergy''

To the Editor:

We would like to thank Dr Bryan Stone for his correspondence 1 to our manuscript ''mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach'' in the Journal of Allergy and Clinical Immunology: In Practice. 2 Current CDC guidance advises that any individual with an immediate or severe allergic reaction to the mRNA vaccine or any component of the vaccine (eg, polyethylene glycol [PEG] or polysorbate) should speak to an allergist before they receive the vaccine. Before the development of mRNA COVID-19 vaccines, allergy to PEG in addition to PEG cross-reactivity with polysorbate 80 was uncommonly diagnosed in the field of drug hypersensitivity. However, reports of severe immediate reactions to the mRNA COVID-19 vaccines, clinically compatible with anaphylaxis, have raised public concern. Although the cause of these reactions is not clear, PEG IgE-mediated allergy remains one possibility. There are well-described cases of IgE-mediated allergy to PEG in the literature, and these cases have positive skin testing to PEG. 3, 4 PEG is also the only component of the currently available mRNA COVID-19 vaccines with a known nonirritating skin testing concentration reported in the literature. 3 We do not have data on nonirritating skin testing concentrations for the mRNA vaccines themselves. These mRNA vaccines have been released under emergency use authorization and are not licensed products for skin testing. Another factor to consider is that the vaccine remains a scare and limited resource in contrast to PEG and polysorbate skin testing reagents that are widely available.

Given that there are no FDA-approved mRNA COVID-19 vaccines without PEG, consideration of skin testing with shared decision making offers a viable approach for individuals either with a clinical history suggestive of an IgE-mediated allergy to PEG or a potential anaphylactic reaction to the first dose of the mRNA COVID-19 vaccines (because PEG is the only available testable component). Although negative skin testing when using nonirritating skin testing concentrations does not definitively rule out allergy, a positive skin test is highly suggestive of true allergy. If skin testing is negative, this provides an additional data point that an IgE-mediated allergy was not identified. As such, a non-IgE mechanism, potentially prevented or minimized with premedication such as antihistamines, may have been the reaction mechanism. Negative skin testing can also address allergy fears in less concerning cases, providing visual reassurance for both the patient and provider that it would be reasonable to proceed with vaccination under close observation. Skipping skin testing altogether may miss rare cases of true IgE-mediated allergy especially when considering a group of individuals with a highrisk history. Negative PEG skin testing also is the first step toward providing reassurance that other drugs and products containing PEG will be tolerated. To confirm PEG tolerance, an oral challenge to PEG3350 may also be considered.

Our anecdotal experience in individuals with a history of an immediate reaction to PEG or a derivative to date is reassuring; individuals with negative PEG skin testing have been successfully vaccinated without incident. Similarly, we have evaluated individuals who reacted to the first dose of the mRNA vaccine, had negative PEG skin testing, and subsequently tolerated the mRNA COVID-19 vaccine. Both of these groups otherwise would have been excluded from either initial vaccination or vaccination completion based on CDC guidance.

We would highlight that our algorithm for PEG skin testing, if negative, is followed by a challenge to the vaccine in a closely monitored setting where anaphylaxis can be managed. Currently, the positive and negative predictive value of PEG skin testing for reactions associated to the COVID-19 mRNA vaccines are unknown. We are using skin testing both to ensure that patients potentially allergic to PEG are not unnecessarily excluded from vaccination with the mRNA COVID-19 vaccines and to identify the only testable IgE culprit in the currently available mRNA COVID-19 vaccines. When allergy testing is negative, we suggest shared decision making between the patient and allergist to proceed with vaccination.

PEG skin testing for COVID-19 Allergy

mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach

Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized

Immediate-type hypersensitivity to polyethylene glycols: a review